StockNews.AI
AKTX
StockNews.AI
89 days

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

1. Akari Therapeutics will present at a biotech webinar on May 29. 2. CEO Abizer Gaslightwala will discuss recent corporate developments. 3. Akari is developing a novel ADC, AKTX-101, targeting cancer treatment. 4. AKTX-101 shows prolonged survival in preclinical studies versus traditional ADCs. 5. The drug may synergize with checkpoint inhibitors for enhanced efficacy.

5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentation could attract investor attention and increase stock demand. Historically, biotech presentations have led to positive price movements.

How important is it?

The webinar may provide critical insights on AKTX-101 and the company's future, impacting investor sentiment. Given the unique attributes of AKTX-101, there is a strong chance of heightened interest.

Why Short Term?

Investor sentiment may be positively influenced immediately leading up to the presentation. Previous biotech webinars often result in short-term stock volatility based on presented data.

Related Companies

SPYIBBXBI
Live webcast on Thursday, May 29th at 2:20 PM ET May 22, 2025 09:00 ET  | Source: Akari Therapeutics Plc BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET. Conference Details: Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29th at 2:20 PM ET Presenter: Abizer Gaslightwala, Director, President and CEORegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com. About Akari Therapeutics Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome inhibitor designed to disrupt RNA splicing within cancer cells. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload. For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 AKTX@jtcir.com

Related News